Your browser doesn't support javascript.
loading
Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis.
Prieto-Peña, Diana; Remuzgo-Martínez, Sara; Genre, Fernanda; Pulito-Cueto, Verónica; Atienza-Mateo, Belén; Llorca, Javier; Sevilla-Pérez, Belén; Ortego-Centeno, Norberto; Marquez, Ana; Lera-Gómez, Leticia; Leonardo, María Teresa; Peñalba, Ana; Narváez, Javier; Martín-Penagos, Luis; Rodrigo, Emilio; Miranda-Filloy, José A; Caminal-Montero, Luis; Collado, Paz; Sánchez Pérez, Javier; de Argila, Diego; Rubio, Esteban; León Luque, Manuel; Blanco-Madrigal, Juan María; Galíndez-Agirregoikoa, Eva; Gualillo, Oreste; Martín, Javier; Castañeda, Santos; Blanco, Ricardo; González-Gay, Miguel A; López-Mejías, Raquel.
Afiliación
  • Prieto-Peña D; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
  • Remuzgo-Martínez S; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
  • Genre F; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
  • Pulito-Cueto V; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
  • Atienza-Mateo B; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
  • Llorca J; López Albo´ Post-Residency Programme, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Sevilla-Pérez B; Epidemiology and Computational Biology Department, School of Medicine, Universidad de Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain.
  • Ortego-Centeno N; Division of Paediatrics, Hospital Universitario San Cecilio, Granada, Spain.
  • Marquez A; Department of Medicine, Universidad de Granada, Granada, Spain.
  • Lera-Gómez L; Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain.
  • Leonardo MT; Systemic Autoimmune Disease Unit, Hospital Universitario Clínico San Cecilio, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
  • Peñalba A; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
  • Narváez J; Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Martín-Penagos L; Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Rodrigo E; Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain.
  • Miranda-Filloy JA; Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain.
  • Caminal-Montero L; Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain.
  • Collado P; Division of Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • Sánchez Pérez J; Division of Rheumatology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
  • de Argila D; Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain.
  • Rubio E; Department of Dermatology, Hospital Universitario de La Princesa, Madrid, Spain.
  • León Luque M; Department of Dermatology, Hospital Universitario de La Princesa, Madrid, Spain.
  • Blanco-Madrigal JM; Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Galíndez-Agirregoikoa E; Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Gualillo O; Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain.
  • Martín J; Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain.
  • Castañeda S; SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
  • Blanco R; Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain.
  • González-Gay MA; Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.
  • López-Mejías R; Research Group On Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Avenida Cardenal Herrera Oria s/n, 39011, Santander, Spain.
Sci Rep ; 11(1): 16163, 2021 08 09.
Article en En | MEDLINE | ID: mdl-34373564
ABSTRACT
Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vasculitis por IgA / Inmunoglobulina A / Interleucina-33 / Proteína 1 Similar al Receptor de Interleucina-1 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vasculitis por IgA / Inmunoglobulina A / Interleucina-33 / Proteína 1 Similar al Receptor de Interleucina-1 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: España